Showing results (51-60 of 94) with videos related to

Sort By:
Pageof 10
Leukemia & Lymphoma|July 27, 2025
Real-world utilization of Bruton tyrosine kinase inhibitors in relapsed/refractory chronic lymphocytic leukemia in AustraliaStephen P Mulligan, Philip A Thompson, Joel Wight, et al.
The Lancet. Haematology|February 1, 2023
Treatment approaches for patients with TP53-mutated mantle cell lymphomaThomas E Lew, Adrian Minson, Michael Dickinson, et al.
Internal Medicine Journal|July 27, 2025
Australia and New Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with Bruton's tyrosine kinase inhibitorsMary Ann Anderson, Farrukh T Awan, Leanne Berkahn, et al.
Cancers|March 13, 2024
Venetoclax Initiation in Chronic Lymphocytic Leukemia: International Insights and Innovative Approaches for Optimal Patient CareMary Ann Anderson, Renata Walewska, Fidelma Hackett, et al.
British Journal of Haematology|July 20, 2024
Potential impact of NOTCH1 activation on venetoclax sensitivity in chronic lymphocytic Leukaemia: In vitro insights and clinical implicationsMing-Yuan Gao, Angela Georgiou, Victor S Lin, et al.
Transplantation and Cellular Therapy|May 11, 2026
Infections in the first 30-days after CAR-T therapy in Patients Not Receiving Fluoroquinolone ProphylaxisGemma K Reynolds, Mark R Dowling, Jose Valencia-Klug, et al.
Ejhaem|November 29, 2023
Persistence of UBTF tandem duplications in remission in acute myeloid leukaemiaSean Harrop, Phillip C Nguyen, David Byrne, et al.
Ejhaem|July 18, 2022
Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapySasanka Handunnetti, Mary Ann Anderson, Andrew W Roberts, et al.
Blood|May 6, 2017
Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclaxMary Ann Anderson, Constantine Tam, Thomas E Lew, et al.
Blood Advances|January 15, 2020
Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 monthsThomas E Lew, Mary Ann Anderson, Victor S Lin, et al.
Pageof 10